- Full Year 2024 Eisai Co Ltd Earnings Presentation TranscriptMay 15, 2024
- Eisai Co Ltd Information Meeting TranscriptMar 08, 2024
- Q3 2024 Eisai Co Ltd Earnings Presentation TranscriptFeb 06, 2024
- Eisai Co Ltd Launch of LEQEMBI in Japan TranscriptDec 13, 2023
- Q2 2024 Eisai Co Ltd Earnings Presentation TranscriptNov 07, 2023
- Q1 2024 Eisai Co Ltd Earnings Presentation TranscriptAug 02, 2023
- Eisai Co Ltd Media and Investor Conference TranscriptJul 07, 2023
- Full Year 2023 Eisai Co Ltd Earnings Presentation TranscriptMay 15, 2023
- Eisai Co Ltd Information Meeting TranscriptMar 10, 2023
- Q3 2023 Eisai Co Ltd Earnings Call TranscriptFeb 06, 2023Earnings
- Eisai Co Ltd Approach to US Pricing for LEQEMBI Briefing TranscriptJan 07, 2023
- Eisai Co Ltd Clarity AD Study Briefing TranscriptNov 30, 2022
- Q2 2023 Eisai Co Ltd Earnings Call TranscriptNov 07, 2022Earnings
- Eisai Co Ltd Lecanemab Phase 3 Study Met Primary Endpoint Call TranscriptSep 28, 2022
- Q1 2023 Eisai Co Ltd Earnings Call TranscriptAug 05, 2022Earnings
- Full Year 2022 Eisai Co Ltd Earnings Presentation TranscriptMay 13, 2022
- Eisai Co Ltd Information Meeting TranscriptMar 16, 2022
- Q3 2022 Eisai Co Ltd Earnings Call TranscriptFeb 03, 2022Earnings
- Q2 2022 Eisai Co Ltd Earnings Call TranscriptNov 01, 2021Earnings
- Q1 2022 Eisai Co Ltd Earnings Call TranscriptAug 04, 2021Earnings
- Eisai Co Ltd FDA Grants Accelerated Approval for ADUHELM Presentation TranscriptJun 09, 2021
- Full Year 2021 Eisai Co Ltd Earnings Call TranscriptMay 12, 2021Earnings
- Eisai Co Ltd Information Meeting TranscriptMar 26, 2021
- Q3 2021 Eisai Co Ltd Earnings Call TranscriptFeb 03, 2021Earnings
- Q2 2021 Eisai Co Ltd Earnings Call TranscriptNov 05, 2020Earnings
- Q1 2021 Eisai Co Ltd Earnings Call TranscriptAug 03, 2020Earnings
- Full Year 2020 Eisai Co Ltd Earnings Call TranscriptMay 13, 2020Earnings
- Eisai Co Ltd Information Meeting TranscriptMar 06, 2020
- Q3 2020 Eisai Co Ltd Earnings Presentation and Conference Call TranscriptJan 31, 2020
- Full Year 2019 Eisai Co Ltd Earnings Presentation and Conference Call TranscriptMay 13, 2019
- Eisai Co Ltd Information Meeting TranscriptMar 08, 2019
Eisai Co Ltd Lecanemab Phase 3 Study Met Primary Endpoint Call Transcript
Good afternoon. We now start explanation meeting for Recanemab Phase III Clarity AD study top line results, which was announced at 8:30 this morning. Thank you for joining this meeting today.
I will facilitate this meeting. My name is Sasaki from Corporate Communications. This meeting has a hybrid format with participants in this room and those connected via telephone. And as a countermeasure against COVID-19, we ask the participants in this room to wear masks. Thank you for your cooperation. Those in the room here, you had the press release announced today in presentation slides distributed on the table. Please confirm that. And those who are connected via telephone, you can see the presentation slides posted on our website. And we have simultaneous interpretation of English and Japanese: channel 1 is Japanese; English, channel #2.
Let me introduce the presenter today, CEO Haruo Naito; global AD Officer, Ivan Chan; Neurology Chief Discovery Officer, Teiji Kimura are also with us to respond to the Q&A session.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)